- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03357289
Mix Vaccine for Metastatic Kidney Cancer
Safety and Efficacy Study of Mix Vaccine in Kidney Cancer Patient
Study Overview
Status
Intervention / Treatment
Detailed Description
By enrolling patients with small metastases of kidney cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of mix vaccine.
The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510665
- Cancer institute of Fuda cancer hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
- Body tumor 1-6, the maximum tumor length < 2 cm
- KPS ≥ 70, lifespan > 6 months
- Platelet count ≥ 80×109/L,white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L
Exclusion Criteria:
- Patients with cardiac pacemaker
- Patients with brain metastasis
- Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mix vaccine
In this group, the patients will receive mix vaccine.
The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
|
Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
Other Names:
|
No Intervention: Control
In this group, the patients will receive no special treatment and as a control group.
The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relief degree of tumors
Time Frame: 3 months
|
It will be evaluated by the Response Evaluation Criteria in Solid Tumors(RECIST)
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progress free survival(PFS)
Time Frame: 1 year
|
The duration from the beginning of treatment to cancer recurrence or progression
|
1 year
|
Overall survival(OS)
Time Frame: 3 years
|
The duration from the beginning of treatment to patient death
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- kidney cancer MV
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastasis From Malignant Tumor of Kidney (Disorder)
-
NanobiotixRecruitingMetastatic Renal Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck | Radiotherapy | Immunotherapy | Microsatellite Instability-High Solid Malignant Tumour | Metastasis From Malignant Tumor of Liver | Metastasis From Malignant Tumor of Cervix | Metastasis From Malignant Melanoma of Skin (Disorder) and other conditionsUnited States
-
Curium US LLCCompletedMetastasis From Malignant Tumor of Prostate (Disorder)United States
-
Istituto Clinico HumanitasActive, not recruitingMetastasis From Malignant Tumor of Soft TissuesItaly
-
Curium US LLCActive, not recruitingMetastasis From Malignant Tumor of ProstateUnited States, France, Spain, Italy
-
Aadi Bioscience, Inc.RecruitingMalignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic NeoplasmKorea, Republic of, United States, Puerto Rico
-
Hospital Universitario Virgen de la ArrixacaNot yet recruitingLiver Diseases | Liver Transplantation | Liver Neoplasms | Gastrointestinal Stromal Tumors | Metastasis | Liver Metastases | Liver Transplant; Complications | Liver Cancer | Liver Transplant Disorder | Liver Carcinoma | GIST, Malignant | GIST | Metastases | Metastatic Liver Cancer | Gastrointestinal Stromal Tumor of... and other conditionsSpain
-
Centre Hospitalier Universitaire VaudoisRecruitingMetastasis From Malignant Melanoma of Skin (Diagnosis)Switzerland
-
Susan Chi, MDBristol-Myers Squibb; Epizyme, Inc.RecruitingChordoma | Epithelioid Sarcoma | Atypical Teratoid Rhabdoid Tumor | INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors | SMARCA4-deficient Primary CNS Malignant Tumors | Malignant Rhabdoid Tumor (MRT) | Rhabdoid Tumor of the Kidney (RTK)United States
-
Syndax PharmaceuticalsCompletedSolid Tumor | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | Metastatic TumorUnited States
-
Eli Lilly and CompanyCompletedSolid Tumor | Malignant Solid Tumor | Metastatic TumorGermany, United States, France
Clinical Trials on Mix vaccine
-
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...Active, not recruitingHPV InfectionUnited States
-
Fuda Cancer Hospital, GuangzhouJinan University GuangzhouCompletedMetastatic Colorectal Cancer | Reaction - Mixed VaccineChina
-
Fuda Cancer Hospital, GuangzhouCompleted
-
Fuda Cancer Hospital, GuangzhouJinan University GuangzhouCompleted
-
Rutgers, The State University of New JerseyCompleted
-
NestléGreat Ormond Street Hospital for Children NHS Foundation TrustCompleted
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1China
-
Steno Diabetes Center CopenhagenDSM Nutritional Products, Inc.CompletedType 1 Diabetes | Diabetic Kidney Disease | Albuminuria | NephropathyDenmark
-
Prollergy dba Ready Set FoodObvioHealthNot yet recruitingFood Allergy in Infants
-
Hebei Medical UniversityCompletedAneurysmal Subarachnoid HemorrhageChina